多参数前列腺MRI阴性患者的处理:AJR专家小组叙述性综述
多参数MRI(mpMRI)用于PSA升高患者的风险分层,多数有临床意义的前列腺癌可被检出,而国际指南已推荐其作为前列腺穿刺前的二次筛查。对于mpMRI阴性(PI-RADS 1或2类)患者的管理尚不明确,本AJR专家小组叙述性综述总结相关文献并给出处理指导。
要点
- 平均风险患者mpMRI阴性后不应常规行系统穿刺,高风险患者则应考虑穿刺。
- mpMRI阴性后选择PSA筛查而非穿刺者,应设定重复MRI的明确触发条件。
- 现有高级别证据不足以支持常规用血清/尿液标志物、AI或PSMA PET决定是否穿刺。
核心结论
- mpMRI阴性(PI-RADS 1或2类)后,平均风险患者不应常规行系统穿刺,高风险患者应考虑穿刺;选择PSA筛查者需设定重复MRI的明确触发条件。
研究设计与样本
- AJR专家小组叙述性综述,汇总PSA升高且前列腺mpMRI阴性患者的相关文献并给出管理指导。
诊断标准与关键数值
- mpMRI阴性定义为PI-RADS 1类或2类。
- 平均风险患者mpMRI阴性后不应常规行系统穿刺,高风险患者应考虑穿刺。
临床应用与阅片要点
- mpMRI阴性(PI-RADS 1或2类)后,平均风险患者不应常规行系统穿刺。
- 高风险患者mpMRI阴性后应考虑系统穿刺。
- mpMRI阴性后选择PSA筛查而非穿刺者,应建立重复MRI的明确触发条件。
- mpMRI阴性且穿刺阴性者,按患者风险级别遵循其医疗从业者偏好的指南进行后续PSA筛查。
- 现有高级别证据不足,不支持常规使用辅助血清或尿液生物标志物、人工智能或PSMA PET决定mpMRI阴性后是否穿刺。
局限性
- 原文指出,支持mpMRI阴性后常规使用辅助血清或尿液生物标志物、人工智能或PSMA PET决定是否穿刺的高级别数据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Multiparametric MRI (mpMRI) of the prostate aids risk stratification of patients with elevated PSA levels. Although most clinically significant prostate cancers are detected by mpMRI, insignificant cancers are less evident. Thus, multiple international prostate cancer guidelines now endorse routine use of prostate MRI as a secondary screening test before prostate biopsy. Nonetheless, management of patients with negative mpMRI results (defined as PI-RADS category 1 or 2) remains unclear. This AJR Expert Panel Narrative Review summarizes the available literature on patients with an elevated screening PSA level and a negative prostate mpMRI result and provides guidance for these patients' management. Systematic biopsy should not be routinely performed after a negative mpMRI examination in patients at average risk but should be considered in patients at high risk. In patients who undergo PSA screening rather than systematic biopsy after negative mpMRI, clear triggers should be established for when to perform a repeat MRI examination. Patients with a negative MRI result followed by negative biopsy should follow their health care practitioners' preferred guidelines concerning subsequent PSA screening for the patient's risk level. Insufficient high-level data exist to support routine use of adjunctive serum or urine biomarkers, artificial intelligence, or PSMA PET to determine the need for prostate biopsy after a negative mpMRI examination.
引用
- Tan N, Pollock JR, Margolis DJA, et al. Management of Patients With a Negative Multiparametric Prostate MRI Examination: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2023. PMID: 37877601. doi:10.2214/AJR.23.29969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。